A Novel Method to Estimate Levels of Receptors Using an Allosteric Modulator: Focus on Muscarinic M1 Receptor.
Autoradiography
Muscarinic M1 receptor
Muscarinic receptors
Phosphor imaging
Radioligand binding
Tissue homogenization
Journal
Methods in molecular biology (Clifton, N.J.)
ISSN: 1940-6029
Titre abrégé: Methods Mol Biol
Pays: United States
ID NLM: 9214969
Informations de publication
Date de publication:
2023
2023
Historique:
medline:
21
7
2023
pubmed:
19
7
2023
entrez:
18
7
2023
Statut:
ppublish
Résumé
This chapter outlines some of the general principles that need to be considered when developing a radioligand binding assay to measure the affinity and density of radioligand binding to a receptor in tissue or on cells. In addition it describes an innovative step forward in using radioligand binding assays to measure levels of muscarinic M1 receptors in human postmortem CNS, using both membrane binding and in situ radioligand binding. These examples show how, using receptor-specific allosteric modulators, it is possible to gain an estimate of the density of a single receptor using a radioligand that is not totally specific to the target site of interest. Given there is a growing understanding that there are problems with antibodies not showing specificity to their supposed target protein, well-characterized radioligand binding techniques still provide an important tool when studying receptor density in tissues and cells.
Identifiants
pubmed: 37464158
doi: 10.1007/978-1-0716-3307-6_1
doi:
Substances chimiques
Receptor, Muscarinic M1
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1-13Informations de copyright
© 2023. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.
Références
McKinney M (2006) Practical aspects of radioligand binding. Curr Protoc Pharmacol Suppl 33:1.3.1–1.3.42
McCrea KE, Herzog H (2000) Radioligand binding studies. In: Balasubramania A (ed) Neuropeptide Y protocols. Humana Press, London
Mancama D, Arranz MJ, Landau S, Kerwin R (2003) Reduced expression of the muscarinic 1 receptor cortical subtype in schizophrenia. Am J Med Genet B Neuropsychiatr Genet 119:2–6
doi: 10.1002/ajmg.b.20020
Dean B, McLeod M, Keriakous D, McKenzie J, Scarr E (2002) Decreased muscarinic(1) receptors in the dorsolateral prefrontal cortex of subjects with schizophrenia. Mol Psychiatry 7:1083–1091
doi: 10.1038/sj.mp.4001199
pubmed: 12476323
Mahmood T, Yang P-C (2012) Western Blot: technique, theory, and trouble shooting. N Am J Med Sci 4:429–434
doi: 10.4103/1947-2714.100998
pubmed: 23050259
pmcid: 3456489
Koussounadis A, Langdon SP, Um IH, Harrison DJ, Smith VA (2015) Relationship between differentially expressed mRNA and mRNA-protein correlations in a xenograft model system. Sci Rep 5:10775
doi: 10.1038/srep10775
pubmed: 26053859
pmcid: 4459080
Pradidarcheep W, Stallen J, Labruyère WT, Dabhoiwala NF, Michel MC, Lamers WH (2009) Lack of specificity of commercially available antisera against muscarinergic and adrenergic receptors. Naunyn Schmiedeberg's Arch Pharmacol 379:397–402
doi: 10.1007/s00210-009-0393-0
Hamdani N, van der Velden J (2009) Lack of specificity of antibodies directed against human beta-adrenergic receptors. Naunyn Schmiedeberg's Arch Pharmacol 379:403–407
doi: 10.1007/s00210-009-0392-1
Ghosh R, Gilda JE, Gomes AV (2014) The necessity of and strategies for improving confidence in the accuracy of western blots. Expert Rev Proteomics 11:549–560
doi: 10.1586/14789450.2014.939635
pubmed: 25059473
pmcid: 4791038
Hansen ES, Knudsen J (1985) Limitations in the use of the enzyme-linked immunosorbent assay (ELISA) for identification and quantification of thermogenin. J Immunol Methods 77:297–304
doi: 10.1016/0022-1759(85)90043-2
pubmed: 3920326
Werry EL, Kassiou M (2022) Measuring affinity of ligands to the oxytocin receptor using radioligand binding. In: Werry EL, Reekie TA, Kassiou M (eds) Oxytocin: methods and protocols. Springer US, New York
doi: 10.1007/978-1-0716-1759-5
Scarr E, Dean B (2008) Muscarinic receptors: do they have a role in the pathology and treatment of schizophrenia? J Neurochem 107:1188–1195
doi: 10.1111/j.1471-4159.2008.05711.x
pubmed: 18957051
Dean B, Crook JM, Opeskin K, Hill C, Keks N, Copolov DL (1996) The density of muscarinic M1 receptors is decreased in the caudate-putamen of subjects with schizophrenia. Mol Psychiatry 1:54–58
pubmed: 9118315
Dean B, Hayes W (1996) Decreased frontal cortical serotonin 2A receptors in schizophrenia. Schizophr Res 21:133–139
doi: 10.1016/0920-9964(96)00034-5
pubmed: 8885041
Sekiguchi H, Pavey G, Dean B (2019) Altered levels of dopamine transporter in the frontal pole and dorsal striatum in schizophrenia. NPJ Schizophr 5:20
doi: 10.1038/s41537-019-0087-7
pubmed: 31792225
pmcid: 6888821
Dean B, Pavey G, Thomas D, Scarr E (2006) Cortical serotonin (7, 1D) and (1F) receptors: effects of schizophrenia, suicide and antipsychotic drug treatment. Schizophr Res 88:265–274
doi: 10.1016/j.schres.2006.07.003
pubmed: 16916599
Jeon WJ, Gibbons AS, Dean B (2013) The use of a modified [3H]4-DAMP radioligand binding assay with increased selectivity for muscarinic M3 receptor shows that cortical CHRM3 levels are not altered in mood disorders. Prog Neuropsychopharmacol Biol Psychiatr 47:7–12
doi: 10.1016/j.pnpbp.2013.08.001
Dean B, Crossland N, Boer S, Scarr E (2008) Evidence for altered post-receptor modulation of the serotonin 2a receptor in schizophrenia. Schizophr Res 104:185–197
doi: 10.1016/j.schres.2008.06.011
pubmed: 18693083
Dean B, Pavey G, Opeskin K (1997) [3H]raclopride binding to brain tissue from subjects with schizophrenia: methodological aspects. Neuropharmacology 36:779–786
doi: 10.1016/S0028-3908(97)00067-1
pubmed: 9225305
Dean B, Soulby A, Evin GM, Scarr E (2008) Levels of [(3)H]pirenzepine binding in Brodmann’s area 6 from subjects with schizophrenia is not associated with changes in the transcription factor SP1 or BACE1. Schizophr Res 106:229–236
doi: 10.1016/j.schres.2008.08.003
pubmed: 18790604
Crook JM, Tomaskovic-Crook E, Copolov DL, Dean B (2001) Low muscarinic receptor binding in prefrontal cortex from subjects with schizophrenia: a study of Brodmann's areas 8, 9, 10, and 46 and the effects of neuroleptic drug treatment. Am J Psychiatr 158:918–925
doi: 10.1176/appi.ajp.158.6.918
pubmed: 11384900
Rodbard D (1981) Mathematics and statistics of ligand assays: an illustrated guide. In: Langan J, Clapp JJ (eds) Ligand assay: analysis of international developments on isotopic and nonisotopic immunoassay. Masson Punlishing USA, Inc, New York
Pavey GM, Copolov DL, Dean B (2002) High-resolution phosphor imaging: validation for use with human brain tissue sections to determine the affinity and density of radioligand binding. J Neurosci Method 116:157–163
doi: 10.1016/S0165-0270(02)00036-5
Dean B, Opeskin K, Pavey G, Naylor L, Hill C, Keks N et al (1995) [3H]paroxetine binding is altered in the hippocampus but not the frontal cortex or caudate nucleus from subjects with schizophrenia. J Neurochem 64:1197–1202
doi: 10.1046/j.1471-4159.1995.64031197.x
pubmed: 7861151
Conn PJ, Christopoulos A, Lindsley CW (2009) Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders. Nat Rev Drug Disc 8:41–54
doi: 10.1038/nrd2760
Ma L, Seager MA, Wittmann M, Jacobson M, Bickel D, Burno M et al (2009) Selective activation of the M1 muscarinic acetylcholine receptor achieved by allosteric potentiation. Proc Natl Acad Sci U S A 106:15950–15955
doi: 10.1073/pnas.0900903106
pubmed: 19717450
pmcid: 2732705
Shirey JK, Brady AE, Jones PJ, Davis AA, Bridges TM, Kennedy JP et al (2009) A selective allosteric potentiator of the M1 muscarinic acetylcholine receptor increases activity of medial prefrontal cortical neurons and restores impairments in reversal learning. J Neurosci 29:14271–14286
doi: 10.1523/JNEUROSCI.3930-09.2009
pubmed: 19906975
pmcid: 2811323
Dean B, Hopper S, Conn PJ, Scarr E (2016) Changes in BQCA allosteric modulation of [3H]NMS binding to human cortex within schizophrenia and by divalent cations. Neuropsychopharmacology 41:1620–1628
doi: 10.1038/npp.2015.330
pubmed: 26511338
Hopper S, Pavey GM, Gogos A, Dean B (2019) Widespread changes in positive allosteric modulation of the muscarinic M1 receptor in some participants with schizophrenia. Int J Neuropsychopharmacol 22:640–650
doi: 10.1093/ijnp/pyz045
pubmed: 31428788
pmcid: 6822142
Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248–254
doi: 10.1016/0003-2697(76)90527-3
pubmed: 942051
Dean B, Pavey G, Chai SY, Mendelsohn FAO (1999) The localisation and quantification of molecular changes in the human brain using in situ radioligand binding and autoradiography. In: Dean B, Kleinman JE, Hyde TM (eds) Using CNS tissue in psychiatric research: a practical guide. Harwood Academic Press, Amsterdam
doi: 10.4324/9780203304273
Murphree SS, Saffitz JE (1987) Quantitative autoradiographic delineation of the distribution of beta-adrenergic receptors in canine and feline left ventricular myocardium. Circ Res 60:568–579
doi: 10.1161/01.RES.60.4.568
pubmed: 3036392
Timp W, Timp G (2020) Beyond mass spectrometry, the next step in proteomics. Science. Advances 6:eaax8978